Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Dr. Reddy's Laboratories ...

    NYSE: RDY · Real-Time Price · USD
    15.80
    -0.37 (-2.29%)
    At close: Jun 13, 2025, 3:59 PM
    16.00
    1.23%
    After-hours: Jun 13, 2025, 05:15 PM EDT
    -2.29%
    Bid 15.65
    Market Cap 13.15B
    Revenue (ttm) 311.31B
    Net Income (ttm) 53.68B
    EPS (ttm) 0.79
    PE Ratio (ttm) 20.01
    Forward PE 0.23
    Analyst Strong Buy
    Ask 16
    Volume 1,519,929
    Avg. Volume (20D) 2,127,692
    Open 15.93
    Previous Close 16.17
    Day's Range 15.74 - 15.97
    52-Week Range 12.26 - 16.89
    Beta 0.39

    About RDY

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol RDY
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for RDY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 week ago
    +5.29%
    Dr. Reddy's Laboratories shares are trading higher... Unlock content with Pro Subscription
    1 month ago
    +3.96%
    Dr. Reddy's Laboratories shares are trading hgher on possible continued strength after reporting better-than-expected Q4 financial results on Friday.
    news image

    1 week ago · zacks.com

    RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar

    Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.

    news image

    1 week ago · businesswire.com

    Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

    HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #Alvotech--Alvotech and Dr. Reddy's Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).

    news image

    4 weeks ago · seekingalpha.com

    Dr. Reddy's Continues To Be A Good Buy At Current Valuation

    I reiterate my strong buy rating on Dr. Reddy's Laboratories due to its attractive valuation and underappreciated growth potential beyond Revlimid. Recent results exceeded expectations, with 20% YoY r...

    news image

    1 month ago · zacks.com

    RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up

    Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

    1 month ago · youtube.com

    Generics won't be affected by Trump's pricing policy, says Dr. Reddy's

    Erez Israeli, CEO of Dr. Reddy's, discusses the potential impact of Trump's proposed drug pricing changes, noting that "generics normally give significant discounts," and shares how the company plans ...

    news image

    1 month ago · seekingalpha.com

    Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript

    Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q4 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Richa Periwal - Head, IR and Analytics Erez Israeli - CEO M V Narasimham - CF...

    news image

    1 month ago · businesswire.com

    Dr. Reddy's Q4 & Full Year FY25 Financial Results

    HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and year ended March 31, 2025.

    news image

    2 months ago · zacks.com

    RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar

    Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.

    news image

    2 months ago · zacks.com

    FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review

    Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.

    news image

    2 months ago · businesswire.com

    Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

    HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #AVT03--Alvotech and Dr. Reddy's announce FDA acceptance of Biologic License Application for AVT03, a proposed biosimilar to Prolia® and...

    Add to Watchlist